REGN15160
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 23, 2023
Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19
(clinicaltrials.gov)
- P1 | N=104 | Completed | Sponsor: Regeneron Pharmaceuticals | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
September 02, 2022
Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19
(clinicaltrials.gov)
- P1 | N=104 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 10, 2022
Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19
(clinicaltrials.gov)
- P1 | N=128 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 24, 2022
Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody(Ies) in Adult Healthy Volunteers as Related to COVID
(clinicaltrials.gov)
- P1 | N=128 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1